From allergies and insect bites to sunburn and irritation, human skin can succumb to a variety of conditions including acne, psoriasis, blisters, hives, actinic keratosis, rosacea, and carbuncles.

Skin diseases are more common than many think; you currently form 1.79% of the global burden of disease.

Zoom to the US, the American Academy of Dermatology (AAD) reports that 84.5 million Americans – 1 in 4 – are affected by skin diseases.

In addition to the physical and mental impairments, skin diseases can also represent a financial burden. skin diseases costs the US healthcare system $75 billion in costs for medical, preventative, and prescription and non-prescription drugs.

For every third American with skin disease, the AAD reports that a dermatologist only saw one.

To make matters worse, the Association of Dermatologists also observed that acne has become a significant problem among teenagers – more than 85% of young people suffer from at least one form of acne.

Demand for effective therapies is growing as case numbers continue to rise. Fortunately, there are a large number of drugs from companies like AbbVie Inc. ABBV, GSK plc GSK, Eli Lilly and Co. LLYand Viatris Inc. VTRS have been approved for the treatment of various dermatological diseases.

These drugs are contributing to the growth of the global dermatology treatment market. That market The size was US$36.82 billion in 2019 and is projected to reach US$63.99 billion by 2027, growing at a compound annual growth rate (CAGR) of 12.9% over the forecast period.

For a company like Jupiter Wellness Inc. JUPWthat drives the research, development and testing of new therapies, the growth and needs of the market could present opportunities.

The Company’s clinical pipeline of prescription skin care therapeutics addresses health concerns such as eczema, burns, herpes, cold sores and skin cancer.

Founded in 2018, Jupiter Wellness is engaged in the manufacture, distribution and marketing of early stage consumer products…